Reprogramming Protein Delivery via Cationic Lipid Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer, particularly brain tumors and breast cancer, face challenges in effectively converting cancer cells into normal cells, with existing compositions and proteins not adequately addressing the need for in vivo cell reprogramming for therapeutic efficacy.
Innovation Solution
The use of pharmaceutical compositions comprising protein transduction reagents non-covalently bound to reprogramming proteins such as Sox2, Oct4, and Nanog, which are administered to subjects to induce in vivo cell conversion, allowing for the transformation of cancer cells into normal cells or transient multipotent stem cells that differentiate into non-cancerous cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compositions and proteins are used for cancer treatment, then some therapeutic effect is achieved, but in vivo cell reprogramming capability is insufficient
Solution Approach 1:
The patent combines reprogramming proteins (Oct4, Sox2, Nanog) with protein transduction reagents into a single composite composition. This merging enables the delivery system to simultaneously provide both the reprogramming capability and the therapeutic effect, resolving the contradiction between reliable therapy and adaptive reprogramming function.
Solution Approach 2:
The invention uses composite material structure where reprogramming proteins are non-covalently bound to cationic lipid polymers. This composite approach allows the composition to exhibit both the stability needed for reliable therapy and the functional versatility for in vivo cell reprogramming, addressing the technical contradiction.
2Object-generated harmful factors
If reprogramming proteins are administered to convert cancer cells, then tumorigenicity is reduced, but delivery efficiency to target cells is insufficient
Solution Approach 1:
The patent introduces protein transduction reagents as intermediary carriers that facilitate the delivery of reprogramming proteins to cancer cells. These cationic lipid polymer intermediaries enable efficient cellular uptake and intracellular delivery, resolving the contradiction between reducing tumorigenicity and achieving sufficient delivery efficiency.
Solution Approach 2:
The invention modifies the physical and chemical parameters of the reprogramming proteins by non-covalent binding to cationic lipid polymers. This parameter change enhances cellular permeability and delivery efficiency while maintaining the biological function of the proteins to reduce tumorigenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the in vivo conversion of cancer cells into normal cells, reducing tumorigenicity and metastatic properties, as demonstrated by significant reductions in tumor volume, weight, and metastasis, along with prolonged survival in animal models, highlighting a novel and effective method for cancer treatment.
Implementation Method 1
a protein transduction reagent, which comprises a cation reagent and a lipid
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 2D~2F
AI summary
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent- modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein- induced in situ cell reprogramming without administration of nucleic acids to the subject.